[A23-85] Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2024
Project no.:
A23-85
Commission:
Commission awarded on 15.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Combination therapy with bevacizumab for the treatment of adults with metastatic colorectal cancer who have received 2 prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and/or anti-epidermal growth factor receptor agents
Indication of an unquantifiable, but at least considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-85
| Project no. | Title | Status |
|---|---|---|
| A24-09 | Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Addendum to Project A23-85 | Commission completed |
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.